Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2022 and provided recent corporate updates
By Galera Therapeutics
Published - Nov 09, 2022, 07:04 AM ET
Last Updated - Mar 21, 2024, 03:16 PM EDT
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022
One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor outcomes and overall survival maintained compared to placebo
One-year ROMAN follow-up data also showedcisplatin-relatedchronickidneydiseasereduced by 50%in avasopasem patients compared to placebo
Meta-analysis of both randomized placebo-controlled trials of avasopasem (ROMAN and GT-201)furtherunderscores efficacy across all key SOM endpoints
